$9.86
0.10[1.02%]
Last update: 12:25PM Get Real Time Here
ORIC Pharmaceuticals
(NASDAQ:ORIC)ORIC Pharmaceuticals Stock (NASDAQ:ORIC), Analyst Ratings, Price Targets, Predictions
ORIC Pharmaceuticals Inc has a consensus price target of $15.1, established from looking at the 28 latest analyst ratings. The last 3 analyst ratings were released from JP Morgan, HC Wainwright & Co., and Oppenheimer on March 27, 2024, March 21, 2024, and March 12, 2024. With an average price target of $18.67 between JP Morgan, HC Wainwright & Co., and Oppenheimer, there's an implied 87.42% upside for ORIC Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
JP Morgan
HC Wainwright & Co.
Oppenheimer
Baird
Wedbush
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for ORIC Pharmaceuticals
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/27/2024 | ORIC | Buy Now | ORIC Pharmaceuticals | $9.96 | 80.72% | JP Morgan | Anupam Rama | $19 → $18 | Maintains | Overweight | Get Alert |
| 03/21/2024 | ORIC | Buy Now | ORIC Pharmaceuticals | $9.96 | 110.84% | HC Wainwright & Co. | Robert Burns | $15 → $21 | Maintains | Buy | Get Alert |
| 03/12/2024 | ORIC | Buy Now | ORIC Pharmaceuticals | $9.96 | 70.68% | Oppenheimer | Matthew Biegler | $14 → $17 | Maintains | Outperform | Get Alert |
| 03/12/2024 | ORIC | Buy Now | ORIC Pharmaceuticals | $9.96 | 151% | Baird | Colleen Kusy | $27 → $25 | Reiterates | Outperform → Outperform | Get Alert |
| 03/12/2024 | ORIC | Buy Now | ORIC Pharmaceuticals | $9.96 | 100.8% | Wedbush | David Nierengarten | → $20 | Reiterates | Outperform → Outperform | Get Alert |
| 03/01/2024 | ORIC | Buy Now | ORIC Pharmaceuticals | $9.96 | 100.8% | Wedbush | David Nierengarten | $12 → $20 | Maintains | Outperform | Get Alert |
| 02/23/2024 | ORIC | Buy Now | ORIC Pharmaceuticals | $9.96 | — | Cantor Fitzgerald | Prakhar Agrawal | — | Initiates | → Overweight | Get Alert |
| 12/13/2023 | ORIC | Buy Now | ORIC Pharmaceuticals | $9.96 | 50.6% | HC Wainwright & Co. | Robert Burns | $16 → $15 | Maintains | Buy | Get Alert |
| 10/26/2023 | ORIC | Buy Now | ORIC Pharmaceuticals | $9.96 | 60.64% | HC Wainwright & Co. | Robert Burns | $13 → $16 | Maintains | Buy | Get Alert |
| 10/23/2023 | ORIC | Buy Now | ORIC Pharmaceuticals | $9.96 | 40.56% | Wedbush | David Nierengarten | → $14 | Reiterates | Outperform → Outperform | Get Alert |
| 09/22/2023 | ORIC | Buy Now | ORIC Pharmaceuticals | $9.96 | 40.56% | Wedbush | David Nierengarten | → $14 | Initiates | → Outperform | Get Alert |
| 08/16/2023 | ORIC | Buy Now | ORIC Pharmaceuticals | $9.96 | 171.08% | Baird | Michael Ulz | $15 → $27 | Maintains | Outperform | Get Alert |
| 08/15/2023 | ORIC | Buy Now | ORIC Pharmaceuticals | $9.96 | 30.52% | HC Wainwright & Co. | Robert Burns | $14 → $13 | Maintains | Buy | Get Alert |
| 06/08/2023 | ORIC | Buy Now | ORIC Pharmaceuticals | $9.96 | 40.56% | HC Wainwright & Co. | Robert Burns | → $14 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2023 | ORIC | Buy Now | ORIC Pharmaceuticals | $9.96 | 40.56% | HC Wainwright & Co. | Robert Burns | $16 → $14 | Maintains | Buy | Get Alert |
| 04/05/2023 | ORIC | Buy Now | ORIC Pharmaceuticals | $9.96 | -19.68% | Citigroup | Yigal Nochomovitz | $9 → $8 | Maintains | Buy | Get Alert |
| 03/23/2023 | ORIC | Buy Now | ORIC Pharmaceuticals | $9.96 | 60.64% | HC Wainwright & Co. | Robert Burns | → $16 | Upgrade | Neutral → Buy | Get Alert |
| 03/21/2023 | ORIC | Buy Now | ORIC Pharmaceuticals | $9.96 | 50.6% | JP Morgan | Anupam Rama | $16 → $15 | Maintains | Overweight | Get Alert |
| 03/21/2023 | ORIC | Buy Now | ORIC Pharmaceuticals | $9.96 | 50.6% | Guggenheim | Michael Schmidt | → $15 | Downgrade | Buy → Neutral | Get Alert |
FAQ
What is the target price for ORIC Pharmaceuticals (ORIC)?
The latest price target for ORIC Pharmaceuticals (NASDAQ: ORIC) was reported by JP Morgan on March 27, 2024. The analyst firm set a price target for $18.00 expecting ORIC to rise to within 12 months (a possible 82.56% upside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ORIC Pharmaceuticals (ORIC)?
The latest analyst rating for ORIC Pharmaceuticals (NASDAQ: ORIC) was provided by JP Morgan, and ORIC Pharmaceuticals maintained their overweight rating.
When was the last upgrade for ORIC Pharmaceuticals (ORIC)?
The last upgrade for ORIC Pharmaceuticals Inc happened on March 23, 2023 when HC Wainwright & Co. raised their price target to $16. HC Wainwright & Co. previously had a neutral for ORIC Pharmaceuticals Inc.
When was the last downgrade for ORIC Pharmaceuticals (ORIC)?
The last downgrade for ORIC Pharmaceuticals Inc happened on March 21, 2023 when Guggenheim changed their price target from N/A to $15 for ORIC Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for ORIC Pharmaceuticals (ORIC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ORIC Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ORIC Pharmaceuticals was filed on March 27, 2024 so you should expect the next rating to be made available sometime around March 27, 2025.
Is the Analyst Rating ORIC Pharmaceuticals (ORIC) correct?
While ratings are subjective and will change, the latest ORIC Pharmaceuticals (ORIC) rating was a maintained with a price target of $19.00 to $18.00. The current price ORIC Pharmaceuticals (ORIC) is trading at is $9.86, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.